At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Stock futures were rising sharply Monday after the U.S. and China said Monday they reached an agreement to temporarily slash ...

In a post on his Truth Social platform on Sunday, Trump said the order, to be signed at 9 a.m. Monday, will institute a "most favored nation" policy where the U.S. will pay the same price for ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Trump's order seeks to ease regulations to compel more U.S. drug manufacturing. He also plans to assess tariffs on drug ...

Trump’s drug pricing order sparks global pharma sell-off as industry warns of stifled innovation and revenue loss in key US ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

In a way, the requiem of the now-dismantled agency can be told through its people — including some entire families, like the ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.